References
- Ansell SM, Kyle RA, Reeder CB, et al. Diagnosis and management of Waldenström macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines. Mayo Clin Proc. 2010;85:824–833.
- Treon SP. Waldenström’s macroglobulinemia: an indolent B-cell lymphoma with distinct molecular and clinical features. Hematol Oncol. 2013;31:76–80.
- Buske C, Leblond V. How to manage Waldenstrom’s macroglobulinemia. Leukemia. 2013;27:762–772.
- Advani RH, Buggy JJ, Sharman JP, et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol. 2013;31:88–94.
- Treon SP, Tripsas CK, Meid K, et al. Ibrutinib in previously treated Waldenström’s macroglobulinemia. N Engl J Med. 2015;372:1430–1440.
- IMBRUVICA (ibrutinib) prescribing information. Pharmacyclics and Janssen Biotech, Inc. [Internet]. 2014 [cited 2014 Jan 7]. Available from: http://www.imbruvica.com/docs/librariesprovider3/default-document-library/prescribing_information.pdf?sfvrsn =4.
- Kimby E, Treon SP, Anagnostopoulos A, et al. Update on recommendations for assessing response from the Third International Workshop on Waldenstrom’s Macroglobulinemia. Clin Lymphoma Myeloma. 2006;6:380–383.